Methylene blue is neuroprotective against mild traumatic brain injury

Lora Talley Watts, Justin Alexander Long, Jonathan Chemello, Samantha Van Koughnet, Angelica Fernandez, Shiliang Huang, Qiang Shen, Timothy Q. Duong

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Methylene blue (MB) has known energy-enhancing and antioxidant properties. This study tested the hypothesis that MB treatment reduces lesion volume and behavioral deficits in a rat model of mild TBI. In a randomized double-blinded design, animals received either MB (n=5) or vehicle (n=6) after TBI. Studies were performed on 0, 1, 2, 7, and 14 days following an impact to the primary forelimb somatosensory cortex. MRI lesion was not apparent 1 h after TBI, became apparent 3h after TBI, and peaked at 2 days for both groups. The MB-treated animals showed significantly smaller MRI lesion volume than the vehicle-treated animals at all time points studied. The MB-treated animals exhibited significantly improved scores on forelimb placement asymmetry and foot fault tests than did the vehicle-treated animals at all time points studied. Smaller numbers of dark-stained Nissl cells and Fluoro-Jade® positive cells were observed in the MB-treated group than in vehicle-treated animals 14 days post-TBI. In conclusion, MB treatment minimized lesion volume, behavioral deficits, and neuronal degeneration following mild TBI. MB is already approved by the United States Food and Drug Administration (FDA) to treat a number of indications, likely expediting future clinical trials in TBI.

Original languageEnglish (US)
Pages (from-to)1063-1071
Number of pages9
JournalJournal of Neurotrauma
Volume31
Issue number11
DOIs
StatePublished - Jun 1 2014

Fingerprint

Brain Concussion
Methylene Blue
Forelimb
Somatosensory Cortex
United States Food and Drug Administration
Traumatic Brain Injury
Foot
Cause of Death
Antioxidants
Clinical Trials

Keywords

  • antioxidant
  • mitochondria
  • MRI
  • oxidative stress
  • vasogenic edema

ASJC Scopus subject areas

  • Clinical Neurology
  • Medicine(all)

Cite this

Talley Watts, L., Long, J. A., Chemello, J., Van Koughnet, S., Fernandez, A., Huang, S., ... Duong, T. Q. (2014). Methylene blue is neuroprotective against mild traumatic brain injury. Journal of Neurotrauma, 31(11), 1063-1071. https://doi.org/10.1089/neu.2013.3193

Methylene blue is neuroprotective against mild traumatic brain injury. / Talley Watts, Lora; Long, Justin Alexander; Chemello, Jonathan; Van Koughnet, Samantha; Fernandez, Angelica; Huang, Shiliang; Shen, Qiang; Duong, Timothy Q.

In: Journal of Neurotrauma, Vol. 31, No. 11, 01.06.2014, p. 1063-1071.

Research output: Contribution to journalArticle

Talley Watts, L, Long, JA, Chemello, J, Van Koughnet, S, Fernandez, A, Huang, S, Shen, Q & Duong, TQ 2014, 'Methylene blue is neuroprotective against mild traumatic brain injury', Journal of Neurotrauma, vol. 31, no. 11, pp. 1063-1071. https://doi.org/10.1089/neu.2013.3193
Talley Watts L, Long JA, Chemello J, Van Koughnet S, Fernandez A, Huang S et al. Methylene blue is neuroprotective against mild traumatic brain injury. Journal of Neurotrauma. 2014 Jun 1;31(11):1063-1071. https://doi.org/10.1089/neu.2013.3193
Talley Watts, Lora ; Long, Justin Alexander ; Chemello, Jonathan ; Van Koughnet, Samantha ; Fernandez, Angelica ; Huang, Shiliang ; Shen, Qiang ; Duong, Timothy Q. / Methylene blue is neuroprotective against mild traumatic brain injury. In: Journal of Neurotrauma. 2014 ; Vol. 31, No. 11. pp. 1063-1071.
@article{0811adc89a8c4f8abbc002ab9c047a44,
title = "Methylene blue is neuroprotective against mild traumatic brain injury",
abstract = "Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Methylene blue (MB) has known energy-enhancing and antioxidant properties. This study tested the hypothesis that MB treatment reduces lesion volume and behavioral deficits in a rat model of mild TBI. In a randomized double-blinded design, animals received either MB (n=5) or vehicle (n=6) after TBI. Studies were performed on 0, 1, 2, 7, and 14 days following an impact to the primary forelimb somatosensory cortex. MRI lesion was not apparent 1 h after TBI, became apparent 3h after TBI, and peaked at 2 days for both groups. The MB-treated animals showed significantly smaller MRI lesion volume than the vehicle-treated animals at all time points studied. The MB-treated animals exhibited significantly improved scores on forelimb placement asymmetry and foot fault tests than did the vehicle-treated animals at all time points studied. Smaller numbers of dark-stained Nissl cells and Fluoro-Jade{\circledR} positive cells were observed in the MB-treated group than in vehicle-treated animals 14 days post-TBI. In conclusion, MB treatment minimized lesion volume, behavioral deficits, and neuronal degeneration following mild TBI. MB is already approved by the United States Food and Drug Administration (FDA) to treat a number of indications, likely expediting future clinical trials in TBI.",
keywords = "antioxidant, mitochondria, MRI, oxidative stress, vasogenic edema",
author = "{Talley Watts}, Lora and Long, {Justin Alexander} and Jonathan Chemello and {Van Koughnet}, Samantha and Angelica Fernandez and Shiliang Huang and Qiang Shen and Duong, {Timothy Q.}",
year = "2014",
month = "6",
day = "1",
doi = "10.1089/neu.2013.3193",
language = "English (US)",
volume = "31",
pages = "1063--1071",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Methylene blue is neuroprotective against mild traumatic brain injury

AU - Talley Watts, Lora

AU - Long, Justin Alexander

AU - Chemello, Jonathan

AU - Van Koughnet, Samantha

AU - Fernandez, Angelica

AU - Huang, Shiliang

AU - Shen, Qiang

AU - Duong, Timothy Q.

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Methylene blue (MB) has known energy-enhancing and antioxidant properties. This study tested the hypothesis that MB treatment reduces lesion volume and behavioral deficits in a rat model of mild TBI. In a randomized double-blinded design, animals received either MB (n=5) or vehicle (n=6) after TBI. Studies were performed on 0, 1, 2, 7, and 14 days following an impact to the primary forelimb somatosensory cortex. MRI lesion was not apparent 1 h after TBI, became apparent 3h after TBI, and peaked at 2 days for both groups. The MB-treated animals showed significantly smaller MRI lesion volume than the vehicle-treated animals at all time points studied. The MB-treated animals exhibited significantly improved scores on forelimb placement asymmetry and foot fault tests than did the vehicle-treated animals at all time points studied. Smaller numbers of dark-stained Nissl cells and Fluoro-Jade® positive cells were observed in the MB-treated group than in vehicle-treated animals 14 days post-TBI. In conclusion, MB treatment minimized lesion volume, behavioral deficits, and neuronal degeneration following mild TBI. MB is already approved by the United States Food and Drug Administration (FDA) to treat a number of indications, likely expediting future clinical trials in TBI.

AB - Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Methylene blue (MB) has known energy-enhancing and antioxidant properties. This study tested the hypothesis that MB treatment reduces lesion volume and behavioral deficits in a rat model of mild TBI. In a randomized double-blinded design, animals received either MB (n=5) or vehicle (n=6) after TBI. Studies were performed on 0, 1, 2, 7, and 14 days following an impact to the primary forelimb somatosensory cortex. MRI lesion was not apparent 1 h after TBI, became apparent 3h after TBI, and peaked at 2 days for both groups. The MB-treated animals showed significantly smaller MRI lesion volume than the vehicle-treated animals at all time points studied. The MB-treated animals exhibited significantly improved scores on forelimb placement asymmetry and foot fault tests than did the vehicle-treated animals at all time points studied. Smaller numbers of dark-stained Nissl cells and Fluoro-Jade® positive cells were observed in the MB-treated group than in vehicle-treated animals 14 days post-TBI. In conclusion, MB treatment minimized lesion volume, behavioral deficits, and neuronal degeneration following mild TBI. MB is already approved by the United States Food and Drug Administration (FDA) to treat a number of indications, likely expediting future clinical trials in TBI.

KW - antioxidant

KW - mitochondria

KW - MRI

KW - oxidative stress

KW - vasogenic edema

UR - http://www.scopus.com/inward/record.url?scp=84901981561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901981561&partnerID=8YFLogxK

U2 - 10.1089/neu.2013.3193

DO - 10.1089/neu.2013.3193

M3 - Article

C2 - 24479842

AN - SCOPUS:84901981561

VL - 31

SP - 1063

EP - 1071

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 11

ER -